Blinded, Multicenter Comparison of Methods to Detect a Drug-resistant Mutant of Human Immunodeficiency Virus Type 1 at Low Frequency

Overview

Journal J Clin Microbiol

Specialty Microbiology

Date 2006 Jul 11

PMID 16825395

Citations 63

Authors

Elias K Halvas

Grace M Aldrovandi

Peter Balfe

Ingrid A Beck

Valerie F Boltz

John M Coffin

Lisa M Frenkel

J Darren Hazelwood

Victoria A Johnson

Mary Kearney

Andrea Kovacs

Daniel R Kuritzkes

Karin J Metzner

Dwight V Nissley

Marek Nowicki

Sarah Palmer

Rainer Ziermann

Richard Y Zhao

Cheryl L Jennings

James Bremer

Don Brambilla

John W Mellors

Affiliations

Soon will be listed here.

Abstract

We determined the abilities of 10 technologies to detect and quantify a common drug-resistant mutant of human immunodeficiency virus type 1 (lysine to asparagine at codon 103 of the reverse transcriptase) using a blinded test panel containing mutant-wild-type mixtures ranging from 0.01% to 100% mutant. Two technologies, allele-specific reverse transcriptase PCR and a Ty1HRT yeast system, could quantify the mutant down to 0.1 to 0.4%. These technologies should help define the impact of low-frequency drug-resistant mutants on response to antiretroviral therapy.

Citing Articles

Complete genome characterization of human noroviruses allows comparison of minor alleles during acute and chronic infections.

Kelly D, Jere K, Darby A, Allen D, Iturriza-Gomara M Access Microbiol. 2021; 3(3):000203.

PMID: 34151158 PMC: 8209700. DOI: 10.1099/acmi.0.000203.

Transmitted and Acquired HIV-1 Drug Resistance from a Family: A Case Study.

Yan L, Yu F, Zhang H, Zhao H, Wang L, Liang Z Infect Drug Resist. 2020; 13:3763-3770.

PMID: 33122923 PMC: 7591230. DOI: 10.2147/IDR.S272232.

Fact and Fiction about 1%: Next Generation Sequencing and the Detection of Minor Drug Resistant Variants in HIV-1 Populations with and without Unique Molecular Identifiers.

Zhou S, Swanstrom R Viruses. 2020; 12(8).

PMID: 32759675 PMC: 7472098. DOI: 10.3390/v12080850.

Multi-Laboratory Comparison of Next-Generation to Sanger-Based Sequencing for HIV-1 Drug Resistance Genotyping.

Parkin N, Avila-Rios S, Bibby D, Brumme C, Eshleman S, Harrigan P Viruses. 2020; 12(7).

PMID: 32605062 PMC: 7411816. DOI: 10.3390/v12070694.

Low-Abundance Drug-Resistant HIV-1 Variants in Antiretroviral Drug-Naive Individuals: A Systematic Review of Detection Methods, Prevalence, and Clinical Impact.

Mbunkah H, Bertagnolio S, Hamers R, Hunt G, Inzaule S, Wit T J Infect Dis. 2019; 221(10):1584-1597.

PMID: 31809534 PMC: 7184901. DOI: 10.1093/infdis/jiz650.

References

HANCE A, Lemiale V, Izopet J, Lecossier D, Joly V, Massip P . Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol. 2001; 75(14):6410-7. PMC: 114364. DOI: 10.1128/JVI.75.14.6410-6417.2001. View

OMeara D, Wilbe K, Leitner T, Hejdeman B, Albert J, Lundeberg J . Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing. J Clin Microbiol. 2001; 39(2):464-73. PMC: 87760. DOI: 10.1128/JCM.39.2.464-473.2001. View

Delaugerre C, Valantin M, Mouroux M, Bonmarchand M, Carcelain G, Duvivier C . Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. AIDS. 2001; 15(16):2189-91. DOI: 10.1097/00002030-200111090-00016. View

Fontaine E, Riva C, Peeters M, Schmit J, Delaporte E, Van Laethem K . Evaluation of two commercial kits for the detection of genotypic drug resistance on a panel of HIV type 1 subtypes A through J. J Acquir Immune Defic Syndr. 2001; 28(3):254-8. DOI: 10.1097/00042560-200111010-00008. View

Schuurman R, Brambilla D, de Groot T, Huang D, Land S, Bremer J . Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. AIDS Res Hum Retroviruses. 2002; 18(4):243-8. DOI: 10.1089/088922202753472801. View

Izopet J, Souyris C, Hance A, Sandres-Saune K, Alvarez M, Pasquier C . Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype. J Infect Dis. 2002; 185(10):1506-10. DOI: 10.1086/340215. View

Hirsch M, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes D, DAquila R . Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2003; 37(1):113-28. DOI: 10.1086/375597. View

Metzner K, Bonhoeffer S, Fischer M, Karanicolas R, Allers K, Joos B . Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis. 2003; 188(10):1433-43. DOI: 10.1086/379215. View

Leitner T, Halapi E, Scarlatti G, Rossi P, Albert J, Fenyo E . Analysis of heterogeneous viral populations by direct DNA sequencing. Biotechniques. 1993; 15(1):120-7. View

10.

Coffin J . HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995; 267(5197):483-9. DOI: 10.1126/science.7824947. View

11.

Shi C, Mellors J . A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors. Antimicrob Agents Chemother. 1998; 41(12):2781-5. PMC: 164210. DOI: 10.1128/AAC.41.12.2781. View

12.

Edelstein R, Nickerson D, Tobe V, Frenkel L . Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine. J Clin Microbiol. 1998; 36(2):569-72. PMC: 104580. DOI: 10.1128/JCM.36.2.569-572.1998. View

13.

Palmer S, Kearney M, Maldarelli F, Halvas E, Bixby C, Bazmi H . Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol. 2005; 43(1):406-13. PMC: 540111. DOI: 10.1128/JCM.43.1.406-413.2005. View

14.

Tsongalis G, Gleeson T, Rodina M, Anamani D, Ross J, Joanisse I . Comparative performance evaluation of the HIV-1 LiPA protease and reverse transcriptase resistance assay on clinical isolates. J Clin Virol. 2005; 34(4):268-71. DOI: 10.1016/j.jcv.2005.01.011. View

15.

Palmer S, Boltz V, Maldarelli F, Kearney M, Halvas E, Rock D . Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS. 2006; 20(5):701-10. DOI: 10.1097/01.aids.0000216370.69066.7f. View

16.

Nissley D, Halvas E, Hoppman N, Garfinkel D, Mellors J, Strathern J . Sensitive phenotypic detection of minor drug-resistant human immunodeficiency virus type 1 reverse transcriptase variants. J Clin Microbiol. 2005; 43(11):5696-704. PMC: 1287775. DOI: 10.1128/JCM.43.11.5696-5704.2005. View

17.

Kutyavin I, Afonina I, Mills A, Gorn V, Lukhtanov E, Belousov E . 3'-minor groove binder-DNA probes increase sequence specificity at PCR extension temperatures. Nucleic Acids Res. 1999; 28(2):655-61. PMC: 102528. DOI: 10.1093/nar/28.2.655. View

18.

Deeks S, Wrin T, Liegler T, Hoh R, Hayden M, Barbour J . Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001; 344(7):472-80. DOI: 10.1056/NEJM200102153440702. View

19.

Julias J, Ferris A, Boyer P, Hughes S . Replication of phenotypically mixed human immunodeficiency virus type 1 virions containing catalytically active and catalytically inactive reverse transcriptase. J Virol. 2001; 75(14):6537-46. PMC: 114377. DOI: 10.1128/JVI.75.14.6537-6546.2001. View